文献速递血液净化与透析水电解质与酸碱

拟钙剂与捆绑支付

Calcimimetics and Bundled Reimbursement.
PubMed 文献 · Am J Kidney Dis · 2019-01-03

本文讨论美国 Medicare 透析捆绑支付制度下拟钙剂的报销变化。自 2011 年起透析服务通过 Prospective Payment System 打包支付,口服-only 药物仍单独报销;首个可注射拟钙剂 etelcalcetide 获批后触发至少 2 年过渡支付,最终将拟钙剂纳入透析捆绑。过渡期结束后提供方可能有减少拟钙剂使用的激励,对透析机构和患者健康的财务与临床影响难以预测。

要点

  • Medicare 透析捆绑支付自 2011 年起实施,口服-only 药物仍通过 Part D 单独报销。
  • 首个可注射拟钙剂 etelcalcetide 获批触发至少 2 年过渡支付,最终将拟钙剂纳入透析捆绑。
  • 过渡期结束后提供方可能有减少拟钙剂使用的激励,需密切监测患者结局。

核心结论

  • 拟钙剂纳入透析捆绑支付后,提供方可能面临减少其使用的激励,对透析机构财务和患者健康的影响难以预测。
  • 为确保患者不受不利影响,Medicare 需谨慎将此类药物纳入捆绑并密切监测结局。

研究设计与样本

  • 本文为针对 Medicare 透析支付政策的评论/综述,未报告系统检索范围或样本量。

主要发现

  • 自 2011 年起,Medicare 通过 Prospective Payment System 对透析服务实行捆绑支付。
  • 无注射等效的口服-only 药物目前被排除在捆绑外,通过 Medicare Part D 单独支付。
  • etelcalcetide 作为首个可注射拟钙剂,其引入和获批触发了至少 2 年的过渡支付。
  • 过渡支付最终将导致拟钙剂被纳入透析捆绑。

临床怎么用

  • 肾内科医生应关注拟钙剂纳入捆绑支付后可能出现的处方激励变化。
  • 在过渡期及之后需密切监测接受拟钙剂治疗患者的矿物质代谢和临床结局。

局限性

  • 本文为政策评论,未提供原始研究数据或定量分析。
  • 骨矿物质管理复杂且缺乏循证推荐,难以预测支付政策转变的实际影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since 2011, the Centers for Medicare & Medicaid Services has provided reimbursement for renal dialysis services furnished to Medicare beneficiaries through a bundled payment system known as the Prospective Payment System. Medications that have no injectable equivalent, known as "oral-only medications," are currently excluded from the bundle and are paid separately through Medicare Part D. Thus, before the development of etelcalcetide, the first injectable calcimimetic, calcimimetics were reimbursed outside the bundle. Etelcalcetide's introduction and approval for use in Medicare triggered a transition payment for a minimum of 2 years that will eventually result in the incorporation of calcimimetics into the dialysis bundle. Consequently, providers may face incentives to reduce calcimimetic use when the transition period has expired. The complexity of bone-mineral management in conjunction with the paucity of evidence-based recommendations in this area makes it difficult to predict the impact of this transition. Because these medications are expensive, a poor transition could have financial ramifications for dialysis organizations and potentially patient health. To ensure that patients are not adversely affected, it is critical that Medicare incorporate these medications into the bundle carefully, with close monitoring of outcomes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lin E, Watnick S. Calcimimetics and Bundled Reimbursement. Am J Kidney Dis. 2019. PMID: 30611600. doi:10.1053/j.ajkd.2018.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。